Update on antifungal therapy

Cancer Practice

Volumn 7, Issue 3, 1999, Pages 157-159

  Gigolashvili, Taisia ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LIPOSOME; NYSTATIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANCER PATIENT; CANDIDA; CLINICAL TRIAL; DRUG CHOICE; DRUG FORMULATION; ENCAPSULATION; HUMAN; MYCOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; REVIEW;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; LIPOSOMES; MYCOSES; NEOPLASMS; NYSTATIN; PEPTIDES; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 0032911771     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1999.73011.x     Document Type: Review

References (17)

1. Sanati H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother. 1997;41:2492-2496.
2. Radford SA, Johnson EM, Warnock DW. In vitro studies of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997;41:841-843.
3. Marco F, Pfaller MA, Messer S, et al. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida species. Antimicrob Agents Chemother. 1998;42:161-163.
4. Dupont B, Denning D, Lode H, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. In program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C. 1995:127. Abstract F81.
5. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol. 1997;97: 663-665.
6. AEGIS. Available at: http://www.aegis.com/ni/pubs/drugs/ 11.html. Accessed May 18, 1998.
7. Perfect JR, Cox GM, Dodge RK, et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1996;40:1910-1913.
8. Ramirez JCG. University of Texas Southwestern HIV Clinical Research Group. Available at: http://www.swmed.edu/ home_pages/hivcrg/sch56592.htm. Accessed April 13, 1998.
9. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1997;41:2333-2338.
10. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41:2326-2332.
11. Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991(L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30: 251-255.
12. Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 1997;41: 1957-1960.
13. Mehta RT, Hopfer RL, McQueen T, et al. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother. 1987;31:1901-1903.
14. Mehta RT, Hopfer RL, Gunner LA, et al. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 1987;31:1897-1900.
15. Johnson EM, Ojwang JO, Szekely A, et al. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations: Antimicrob Agents Chemother. 1998;42:1412-1416.
16. Fischer A. Aronex Pharmaceuticals, Inc. Available at: http:// www.aronex.com/noframes/press38.html. Accessed September 28, 1998.
17. Fischer A. Aronex Pharmaceuticals, Inc. Available at: http:// www.aronex.com/noframes/press18.html. Accessed October 1, 1997.